PHGUF Stock - Pharming Group N.V.
Unlock GoAI Insights for PHGUF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $297.20M | $245.32M | $205.62M | $189.85M | $228.39M |
| Gross Profit | $239.99M | $220.10M | $186.93M | $169.67M | $203.06M |
| Gross Margin | 80.7% | 89.7% | 90.9% | 89.4% | 88.9% |
| Operating Income | $-3,507,547 | $-5,387,000 | $18.23M | $27.84M | $82.09M |
| Net Income | $-11,332,296 | $-10,768,736 | $13.67M | $16.00M | $37.75M |
| Net Margin | -3.8% | -4.4% | 6.7% | 8.4% | 16.5% |
| EPS | $-0.02 | $-0.01 | $0.02 | $0.03 | $0.06 |
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Visit WebsiteEarnings History & Surprises
PHGUFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 11, 2026 | — | — | — | — |
Q4 2025 | Nov 6, 2025 | $0.00 | $0.01 | +2122.2% | ✓ BEAT |
Q3 2025 | Jul 31, 2025 | $-0.01 | $0.01 | +195.2% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.02 | $-0.02 | 0.0% | = MET |
Q1 2025 | Mar 13, 2025 | $0.01 | $0.01 | 0.0% | = MET |
Q4 2024 | Oct 24, 2024 | $-0.00 | $-0.00 | -33.3% | ✗ MISS |
Q3 2024 | Aug 1, 2024 | $-0.00 | $-0.00 | -780.0% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-0.01 | $-0.02 | -235.6% | ✗ MISS |
Q1 2024 | Mar 14, 2024 | $-0.00 | $-0.00 | -181.0% | ✗ MISS |
Q4 2023 | Oct 26, 2023 | $0.00 | $0.01 | +138.7% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $0.00 | $0.00 | +100.0% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.01 | $-0.02 | -161.4% | ✗ MISS |
Q1 2023 | Mar 16, 2023 | $-0.01 | $-0.02 | -136.4% | ✗ MISS |
Q4 2022 | Oct 27, 2022 | $0.01 | $0.01 | +73.3% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $0.04 | $0.02 | -55.6% | ✗ MISS |
Q2 2022 | May 12, 2022 | $0.00 | $0.01 | +183.3% | ✓ BEAT |
Q1 2022 | Mar 17, 2022 | $0.00 | $0.00 | +1005.7% | ✓ BEAT |
Q4 2021 | Oct 28, 2021 | $0.01 | $-0.00 | -106.5% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $0.01 | $0.01 | 0.0% | = MET |
Latest News
Pharming Group shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.
📈 PositivePharming Group To Present 12 Abstracts At ACAAI 2025 Highlighting New Data For RUCONEST And Joenja Across Rare Diseases
📈 PositivePharming Group Announces Restructuring With 20% Headcount Reduction To Cut Costs By $10M Annually; Anticipates One-Time Restructuring Costs Of ~$7M To Be Recorded In Q4 2025 In Connection With The Headcount Reduction
📉 NegativePharming Group Gains FDA Priority Review For Leniolisib sNDA In Children With APDS Ages 4 To 11 Years
📈 PositivePharming Group Promoted To Euronext AMX Index From AScX Effective September 22, Reflecting Strong Growth Momentum And Visibility
📈 PositivePharming Group Appoints Kenneth Lynard As Chief Financial Officer Effective October 1, 2025
➖ NeutralFrequently Asked Questions about PHGUF
What is PHGUF's current stock price?
What is the analyst price target for PHGUF?
What sector is Pharming Group N.V. in?
What is PHGUF's market cap?
Does PHGUF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to PHGUF for comparison